|
Synonyms: humZ270 [8] | IPH-2201 | NN8765-3658
Compound class:
Antibody
Comment: Monalizumab (IPH2201) is a humanized IgG4κ anti-NKG2A (KLRC1, CD159a) monoclonal antibody being investigated as an anti-cancer treatment [4,7]. Administered intravenously or subcutaneously. Use of monalizumab is claimed in patent WO2016041947 (called IPH2201 in the patent) [1].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| Bioactivity Comments |
| Patent WO2016041947 provides a binding Kd of ~4ng/ml for IPH2201 interaction with NKG2A [1]. Using a mass of 150KDa as the molecular weight of an average antibody we calculated the molarity provided in the table below for the Kd value. |
| Selectivity at other protein targets | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
